As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect ...
SAB Biotherapeutics (SABS) highlighted multiple presentations made at the 61st Annual Meeting of the European Association for the Study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback